Topical and Systemic Retinoids for the Treatment of Cutaneous Viral Warts

pay.thelady61 shared this article with you from Inoreader Topical and Systemic Retinoids for the Treatment of Cutaneous Viral Warts: A Systematic Review and Meta‐Analysis Via Dermatologic Therapy Abstract Background Cutaneous viral warts, caused by human papillomavirus, often have a self‐limited course. However, some patients experience a recalcitrant disease despite treatment. Retinoids are considered the mainstay of therapy in many dermatologic diseases. Data on their use for viral warts are limited. Objective To systematically review the published evidence on the efficacy and safety of retinoids for the treatment of cutaneous viral warts. Methods A systematic review and meta‐analysis of topical or systemic retinoid treatment for cutaneous viral warts was performed in accordance with the PRISMA statement. The primary outcome was clinical response; secondary outcomes were recurrence rate and adverse events. Results Fourteen publications including 399 patients treated exclusively with retinoids (65% topical, 35% systemic) were evaluated. The complete response rate was 64% (95% CI, 46‐78%; I2=80%) for topical treatment and 61% (95% CI, 44‐76%; I2=69%) for systemic treatment. The most common side effects were irritant contact dermatitis and cheilitis, respectively. Relapse rates were 6% and 17%, respectively. Limitations The reviewed studies were considerably heterogenous and most lacked a control group. Conclusion Both topical and systemic retinoids are effective and safe as monotherapy for cutaneous viral warts. Further studies are required to determine their exact role in this setting. This article is protected by copyright. All rights reserved. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.